Cargando…

Safety of 50,000-100,000 Units of Vitamin D3/Week in Vitamin D-Deficient, Hypercholesterolemic Patients with Reversible Statin Intolerance

BACKGROUND: Vitamin D deficiency (<32 ng/mL) is a reversible cause of statin-intolerance, usually requiring vitamin D3 (50,000-100,000 IU/week) to normalize serum D, allowing reinstitution of statins. Longitudinal safety assessment of serum vitamin D, calcium, and estimated glomerular filtration...

Descripción completa

Detalles Bibliográficos
Autores principales: Jetty, Vybhav, Glueck, Charles J, Wang, Ping, Shah, Parth, Prince, Marloe, Lee, Kevin, Goldenberg, Michael, Kumar, Ashwin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821095/
https://www.ncbi.nlm.nih.gov/pubmed/27114973
http://dx.doi.org/10.4103/1947-2714.179133
_version_ 1782425523229556736
author Jetty, Vybhav
Glueck, Charles J
Wang, Ping
Shah, Parth
Prince, Marloe
Lee, Kevin
Goldenberg, Michael
Kumar, Ashwin
author_facet Jetty, Vybhav
Glueck, Charles J
Wang, Ping
Shah, Parth
Prince, Marloe
Lee, Kevin
Goldenberg, Michael
Kumar, Ashwin
author_sort Jetty, Vybhav
collection PubMed
description BACKGROUND: Vitamin D deficiency (<32 ng/mL) is a reversible cause of statin-intolerance, usually requiring vitamin D3 (50,000-100,000 IU/week) to normalize serum D, allowing reinstitution of statins. Longitudinal safety assessment of serum vitamin D, calcium, and estimated glomerular filtration rate (eGFR) is important. AIMS: Prospectively assess the safety-efficacy of vitamin D3 therapy. MATERIALS AND METHODS: In 282 statin-intolerant hypercholesterolemic patients for 6 months and in 112 of the 282 patients for 12 months, with low-entry serum vitamin D (<32 ng/mL), we assessed safety-efficacy of vitamin D3 therapy (50,000-100,000 IU/week). RESULTS: On mean (66,600 IU) and median (50,000 IU) of vitamin D3/week in 282 patients at 6 months, serum vitamin D rose from pretreatment (21—median) to 46 ng/mL (P < 0.0001), and became high (>100 ng/mL) but not toxic (>150 ng/mL) in 4 patients (1.4%). Median serum calcium was unchanged from entry (9.60 mg/dL) to 9.60 at 6 months (P = .36), with no trend of change (P = .16). Median eGFR was unchanged from entry (84 mL/min/1.73) to 83 at 6 months (P = .57), with no trend of change (P = .59). On vitamin D3 71,700 (mean) and 50,000 IU/week (median) at 12 months in 112 patients, serum vitamin D rose from pretreatment (21—median) to 51 ng/mL (P < 0.0001), and became high (>100 but <150 ng/mL) in 1 (0.9%) at 12 months. Median serum calcium was unchanged from entry (9.60 mg/dL) to 9.60 mg/dL and 9.60 mg/dL at 6 months and 12 months, respectively; P > 0.3. eGFR did not change from 79 mL/min/1.73 at entry to 74 mL/min/1.73 and 77 mL/min/1.73 at 6 months and 12 months, P > 0.3. There was no trend in the change in serum calcium (P > 0.5 for 6 months and 12 months), and no change of eGFR for 6 months and 12 months, P > 0.15. CONCLUSIONS: Vitamin D3 therapy (50,000-100,000 IU/week) was safe and effective when given for 12 months to reverse statin intolerance in patients with vitamin D deficiency. Serum vitamin D rarely exceeded 100 ng/mL, never reached toxic levels, and there were no significant change in serum calcium or eGFR.
format Online
Article
Text
id pubmed-4821095
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-48210952016-04-25 Safety of 50,000-100,000 Units of Vitamin D3/Week in Vitamin D-Deficient, Hypercholesterolemic Patients with Reversible Statin Intolerance Jetty, Vybhav Glueck, Charles J Wang, Ping Shah, Parth Prince, Marloe Lee, Kevin Goldenberg, Michael Kumar, Ashwin N Am J Med Sci Original Article BACKGROUND: Vitamin D deficiency (<32 ng/mL) is a reversible cause of statin-intolerance, usually requiring vitamin D3 (50,000-100,000 IU/week) to normalize serum D, allowing reinstitution of statins. Longitudinal safety assessment of serum vitamin D, calcium, and estimated glomerular filtration rate (eGFR) is important. AIMS: Prospectively assess the safety-efficacy of vitamin D3 therapy. MATERIALS AND METHODS: In 282 statin-intolerant hypercholesterolemic patients for 6 months and in 112 of the 282 patients for 12 months, with low-entry serum vitamin D (<32 ng/mL), we assessed safety-efficacy of vitamin D3 therapy (50,000-100,000 IU/week). RESULTS: On mean (66,600 IU) and median (50,000 IU) of vitamin D3/week in 282 patients at 6 months, serum vitamin D rose from pretreatment (21—median) to 46 ng/mL (P < 0.0001), and became high (>100 ng/mL) but not toxic (>150 ng/mL) in 4 patients (1.4%). Median serum calcium was unchanged from entry (9.60 mg/dL) to 9.60 at 6 months (P = .36), with no trend of change (P = .16). Median eGFR was unchanged from entry (84 mL/min/1.73) to 83 at 6 months (P = .57), with no trend of change (P = .59). On vitamin D3 71,700 (mean) and 50,000 IU/week (median) at 12 months in 112 patients, serum vitamin D rose from pretreatment (21—median) to 51 ng/mL (P < 0.0001), and became high (>100 but <150 ng/mL) in 1 (0.9%) at 12 months. Median serum calcium was unchanged from entry (9.60 mg/dL) to 9.60 mg/dL and 9.60 mg/dL at 6 months and 12 months, respectively; P > 0.3. eGFR did not change from 79 mL/min/1.73 at entry to 74 mL/min/1.73 and 77 mL/min/1.73 at 6 months and 12 months, P > 0.3. There was no trend in the change in serum calcium (P > 0.5 for 6 months and 12 months), and no change of eGFR for 6 months and 12 months, P > 0.15. CONCLUSIONS: Vitamin D3 therapy (50,000-100,000 IU/week) was safe and effective when given for 12 months to reverse statin intolerance in patients with vitamin D deficiency. Serum vitamin D rarely exceeded 100 ng/mL, never reached toxic levels, and there were no significant change in serum calcium or eGFR. Medknow Publications & Media Pvt Ltd 2016-03 /pmc/articles/PMC4821095/ /pubmed/27114973 http://dx.doi.org/10.4103/1947-2714.179133 Text en Copyright: © 2016 North American Journal of Medical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Jetty, Vybhav
Glueck, Charles J
Wang, Ping
Shah, Parth
Prince, Marloe
Lee, Kevin
Goldenberg, Michael
Kumar, Ashwin
Safety of 50,000-100,000 Units of Vitamin D3/Week in Vitamin D-Deficient, Hypercholesterolemic Patients with Reversible Statin Intolerance
title Safety of 50,000-100,000 Units of Vitamin D3/Week in Vitamin D-Deficient, Hypercholesterolemic Patients with Reversible Statin Intolerance
title_full Safety of 50,000-100,000 Units of Vitamin D3/Week in Vitamin D-Deficient, Hypercholesterolemic Patients with Reversible Statin Intolerance
title_fullStr Safety of 50,000-100,000 Units of Vitamin D3/Week in Vitamin D-Deficient, Hypercholesterolemic Patients with Reversible Statin Intolerance
title_full_unstemmed Safety of 50,000-100,000 Units of Vitamin D3/Week in Vitamin D-Deficient, Hypercholesterolemic Patients with Reversible Statin Intolerance
title_short Safety of 50,000-100,000 Units of Vitamin D3/Week in Vitamin D-Deficient, Hypercholesterolemic Patients with Reversible Statin Intolerance
title_sort safety of 50,000-100,000 units of vitamin d3/week in vitamin d-deficient, hypercholesterolemic patients with reversible statin intolerance
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821095/
https://www.ncbi.nlm.nih.gov/pubmed/27114973
http://dx.doi.org/10.4103/1947-2714.179133
work_keys_str_mv AT jettyvybhav safetyof50000100000unitsofvitamind3weekinvitaminddeficienthypercholesterolemicpatientswithreversiblestatinintolerance
AT glueckcharlesj safetyof50000100000unitsofvitamind3weekinvitaminddeficienthypercholesterolemicpatientswithreversiblestatinintolerance
AT wangping safetyof50000100000unitsofvitamind3weekinvitaminddeficienthypercholesterolemicpatientswithreversiblestatinintolerance
AT shahparth safetyof50000100000unitsofvitamind3weekinvitaminddeficienthypercholesterolemicpatientswithreversiblestatinintolerance
AT princemarloe safetyof50000100000unitsofvitamind3weekinvitaminddeficienthypercholesterolemicpatientswithreversiblestatinintolerance
AT leekevin safetyof50000100000unitsofvitamind3weekinvitaminddeficienthypercholesterolemicpatientswithreversiblestatinintolerance
AT goldenbergmichael safetyof50000100000unitsofvitamind3weekinvitaminddeficienthypercholesterolemicpatientswithreversiblestatinintolerance
AT kumarashwin safetyof50000100000unitsofvitamind3weekinvitaminddeficienthypercholesterolemicpatientswithreversiblestatinintolerance